SCHEMBL16396406

SCHEMBL16396406

COc1cc(Cl)cc(C(=O)c2ccncc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ HPGD P15428 1/20 0.51
▸ MAPT P10636 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ CYP1A2 P05177 2/20 0.48
▸ CYP1A1 P04798 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP1B1 Q16678 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.46
▸ RAB9A P51151 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ TUBB4A P04350 1/20 0.43
▸ TUBB P07437 1/20 0.43
▸ TUBA3C P0DPH7 1/20 0.43
▸ TUBA1B P68363 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3920349 0.80 SMN1; SMN2 (0.44) KMT2AMEN1MAPTKDM4ECYP1A2
SCHEMBL9360184 0.78 HPGD (0.76) KMT2AMEN1HPGDMAPTLMNA
SCHEMBL11276575 0.78 LMNA (0.68) KMT2AMEN1HPGDMAPTCYP1A2
SCHEMBL5216406 0.78 KMT2A (0.72) KMT2AMEN1CYP1A2CYP1A1CYP2D6
SCHEMBL30251625 0.74 TPMT (0.61) HPGDKDM4ELMNA
SCHEMBL986399 0.74 HPGD (0.44) HPGDMAPTKDM4ERAB9ANPC1
SCHEMBL1188720 0.74 TPMT (0.61) HPGDKDM4ELMNA
SCHEMBL1188363 0.74 LMNA (0.47) KMT2AMEN1HPGDMAPTLMNA
SCHEMBL5751478 0.73 KDM4E (0.60) KMT2AMEN1HPGDMAPTKDM4E
SCHEMBL1817008 0.73 ALDH1A1 (0.58) KMT2AMEN1HPGDMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562912-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2020-02-18 — — US disclosed
EP-3004057-B1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS C&C RES LAB (KR) 2018-07-25 — — EP disclosed
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2016-04-21 — — US disclosed
EP-3004057-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C Research Laboratories (KR) 2016-04-13 — — EP disclosed
WO-2014196793-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2014-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF STAT3, JAK2, STAT5A KMT2A 3017/4885MEN1 3206/4885HPGD 785/4885
US-10562912-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, STAT5A KMT2A 3017/4885MEN1 3206/4885HPGD 785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback